Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed

Harel Dahari, Amir Shlomai, Scott J Cotler

Journal of Viral Hepatitis

January 2021

[Full Text, Pubmed]

Abstract

We read with interest the study of Goncalves and colleagues1 , presenting a multi-compartmental mathematical model to explain the observed decline of both serum HBV DNA (sDNA) and HBV RNA (sRNA) in chronic HBV-infected patients treated with the core-protein assembly modulator RG7907 for 4 weeks. The authors used their model to predict early sRNA kinetics in chronic HBV-infected patients during nucleosidic analogue (NA) therapy.

Partnerships that get results: Global. Fluid. Connected. Join Us!

Loyola University Medical Center

Department of Medicine

Division of Hepatology

2160 S. First Ave
Mulcahy Center, Rm 1610

Maywood, IL 60153, USA

Email: hdahari@luc.edu

Phone: 708-216-4682

Fax: 708-216-6299